Ascletis Pharma (ASCLF) Stock Price, News & Analysis

Company Overview

Ascletis Pharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the discovery, development, manufacturing and commercialization of innovative therapeutics. The company specializes in small-molecule and fixed-dose combination treatments, with a primary focus on antiviral therapies for hepatitis B, hepatitis C and emerging viral infections. Ascletis also advances a pipeline of oncology candidates targeting hepatocellular carcinoma and other solid tumors.

Since its founding in 2013, Ascletis has progressed multiple drug candidates through preclinical and clinical development. Its antiviral portfolio includes proprietary agents designed to inhibit viral replication and address drug resistance, some of which have advanced into late-stage clinical trials. In oncology, the company’s research leverages targeted small molecules aimed at key signaling pathways implicated in liver cancer and related malignancies.

Ascletis operates research and development centers in China and maintains strategic collaborations with academic institutions and contract research organizations to support its clinical programs. The company’s manufacturing capabilities encompass both active pharmaceutical ingredient production and finished-dosage form assembly, enabling scalable supply for domestic and regional markets. Ascletis seeks to expand its global footprint through partnerships and licensing agreements in North America, Europe and Asia Pacific.

Led by a management team with extensive experience in multinational pharmaceutical and biotechnology enterprises, Ascletis Pharma combines scientific expertise with commercialization know-how. The company’s leadership has guided its transition from a private research venture to a publicly traded entity, with a strategic emphasis on addressing unmet medical needs in viral and oncologic diseases through innovative drug development.

Key Stats

• Today's Range: $1.25 to $1.38
• 50-Day Range: $0.85 to $1.38
• 52-Week Range: $0.16 to $1.38
• Volume: 1,100 shs
• Average Volume: 2,389 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASCLF Stock Analysis - Frequently Asked Questions

How have ASCLF shares performed this year?

Ascletis Pharma's stock was trading at $0.2393 on January 1st, 2025. Since then, ASCLF shares have increased by 476.7% and is now trading at $1.38.

How do I buy shares of Ascletis Pharma?

Shares of ASCLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ASCLF
• CIK: N/A
• Web: www.ascletis.com
• Phone: 86-571-8538-9730
• Fax: N/A
• Employees: 219
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A